Created by BrownHairedGirl
Last edited March 15, 2026
Talk
Natco Pharma
Traded asNSE: NATCOPHARM
BSE: 524816
IndustryPharmaceuticals
Founded1981
Founder(s)sVC Nannapaneni
Headquarters,
Area served
Global
Key people
VC Nannapaneni (Chairman and MD)[1]
Rajeev Nannapaneni (CEO and Vice Chairman)[2]
Websitenatcopharma.co.in

Natco Pharma is an Indian pharmaceutical company based in Hyderabad, which makes finished dosage formulations and active pharmaceutical ingredients. It is the market leader in branded oncology medicines in India,[3] and among the country's top three producers of hepatitis C drugs.[4]

In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.[5] In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[4] In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.[6]

In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[5]

References

  1. ↑ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
  2. ↑ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
  3. ↑ "Natco Pharma lines up 20 `Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
  4. ↑ 4.0 4.1 "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
  5. ↑ 5.0 5.1 "Niche Play". Business Today. Retrieved 19 April 2020.
  6. ↑ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.